Merck Hedges Bets With Keytruda Lung Study
Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don ' t interpret the study as a bet the combination will prove effective.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Merck | Pharmaceuticals | Study | Yervoy